PTHS Q1 2026 Earnings Call Summary

Pelthos Therapeutics Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Net Product Revenue: Increased to $10.7 million in Q1 2026, up 17% from $9.1 million in Q4 2025.
Prescription Units: Rose 25% from 6,312 units in Q4 2025 to 7,884 units in Q1 2026. April 2026 saw a further increase to 3,776 units from 3,309 in March.
Gross to Net (GTN): Reported at 29.1%, with expectations to reach the mid-30% range in the future.
SG&A Expenses: Increased to $21.1 million, a 14% rise from $18.5 million in Q4 2025, primarily due to expanded sales force and increased marketing costs.
Net Loss: Reported at $10.2 million, improved from $21.7 million in Q4 2025.
Cash Position: $32 million in cash and $11.7 million in accounts receivable as of March 31, 2026.

2. Strategic Updates and Business Highlights

Product Launch: ZELSUVMI, a topical treatment for molluscum contagiosum, continues to gain traction, with over 20,000 units dispensed since its launch in July 2025.
Sales Force Expansion: Increased from 50 to 64 representatives, contributing to the growth in prescriptions.
Manufacturing Progress: Ongoing efforts to establish manufacturing for complementary products XEPI and XEGLYZE, with launches expected in early and mid-2027, respectively.
Partnerships: Secured contracts with a major pharmacy benefit manager (PBM), resulting in doubled units dispensed and a 121% increase in prescribers.

3. Forward Guidance and Outlook

Revenue Growth: Management expressed confidence in the revenue growth trajectory, though no specific guidance was provided.
Product Launches: Anticipated launches of XEPI and XEGLYZE are expected to leverage existing sales infrastructure, enhancing operational efficiency.
Cash Flow: The company believes it has sufficient capital to execute its business plans, supported by revenue growth and a recent $50 million term debt loan.

4. Bad News, Challenges, or Points of Concern

Net Loss: Despite improvements, the company continues to operate at a net loss, which could raise concerns among investors regarding profitability.
SG&A Increases: Rising expenses could pressure margins if revenue growth does not keep pace.
Market Competition: The company faces competitive pressures in the dermatology and pediatric markets, particularly as it seeks to establish ZELSUVMI as a first-line treatment.
Seasonality: Treatment uptake may be affected by seasonal factors, including weather and office availability, which could impact prescription volumes.

5. Notable Q&A Insights

Repeat Prescribers: Over 500 repeat prescribers were noted, indicating strong adoption among healthcare providers.
Telehealth Usage: Approximately 10% of prescriptions are fulfilled via mail order, including services like Amazon Pharmacy, though specific telehealth prescription metrics are not available.
Market Dynamics: Dermatologists are currently the primary prescribers, but pediatricians are increasingly adopting ZELSUVMI as a first-line treatment option.
Future Product Strategy: The company remains open to adding complementary products but will focus on maximizing the potential of ZELSUVMI and its upcoming launches before expanding further.

Overall, Pelthos Therapeutics reported a solid quarter with significant growth in revenue and prescriptions for ZELSUVMI, while also preparing for future product launches. However, ongoing net losses and rising expenses present challenges that the company will need to navigate as it seeks to establish itself in the market.

PTHS — Pelthos Therapeutics Inc.